Content area

Abstract

Introduction

The incidence of facial palsy has been rising worldwide, with recent evidence emerging of links to COVID-19 infection. To date, guidance on cost-effective treatments is limited to medication (prednisolone). In terms of physical therapy, neuromuscular retraining (NMR) to restore balanced facial function has been most widely evaluated, but not in terms of cost effectiveness. The added value of telerehabilitation is unknown.

Methods

A multistage technology assessment was conducted, which included the following:

  • • a national survey of current therapy pathways in the UK and patients’ and clinicians’ views on the benefits and challenges of telerehabilitation;
  • • a systematic review of clinical effectiveness trials evaluating facial NMR therapy;
  • • calculation of long-term morbidity costs (national economic burden) based on incidence, patient recovery profiles, health-related quality of life, and national facial palsy treatment costs (valuation of clinical improvements in monetary terms was provided by a national Delphi panel); and
  • • evaluation of the cost effectiveness of telerehabilitation (remote monitoring wearables) added to current face-to-face NMR delivery.

Results

Nationally, approximately five percent of patients with facial palsy (17% of unresolved cases) are referred for facial NMR. The long-term economic burden associated with unresolved cases is estimated to range from GBP351 (EUR417) to GBP584 (EUR692) million, indicating substantial savings if long-term recovery can be improved. Medical treatment costs are GBP86.34 (EUR102) million per annual cohort, and physical and psychological therapy costs are GBP643,292 (EUR762,561). Economic modeling showed that telerehabilitation was cost effective, producing a health gain and a cost-saving of GBP468 (EUR555) per patient. If scaled to the national level for all patients who do not recover fully, an annual saving of GBP3.075 (EUR3.65) million is possible.

Conclusions

Economic modeling indicates that NMR could improve patient outcomes and reduce costs. The national survey demonstrated that access to NMR therapy services is limited, so introduction of telerehabilitation could improve access for currently underserved populations. Future clinical trials need to incorporate economic evaluations to help inform decision-making.

Details

10000008
Title
PD25 Innovation In Facial Palsy Treatment: The Costs And Benefits Of Telerehabilitation Introduced Into Physical Therapy Pathways
Volume
40
Issue
S1
Source details
Abstracts from the HTAi 2024 Meeting in Seville, Spain
Pages
S107-S107
Publication year
2025
Publication date
Jan 2025
Section
Poster Presentations (online)
Publisher
Cambridge University Press
Place of publication
Cambridge
Country of publication
United Kingdom
ISSN
02664623
e-ISSN
14716348
Source type
Scholarly Journal
Language of publication
English
Document type
Conference Proceedings
Publication history
 
 
Online publication date
2025-01-07
Publication history
 
 
   First posting date
07 Jan 2025
ProQuest document ID
3152081054
Document URL
https://www.proquest.com/scholarly-journals/pd25-innovation-facial-palsy-treatment-costs/docview/3152081054/se-2?accountid=208611
Copyright
© The Author(s), 2024. Published by Cambridge University Press. This work is licensed under the Creative Commons Attribution License This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-02-04
Database
ProQuest One Academic